PFE Jan 2024 22.500 put
| Previous Close | 0.2700 |
| Open | 0.2300 |
| Bid | 0.1900 |
| Ask | 0.2500 |
| Strike | 22.50 |
| Expire Date | 2024-01-19 |
| Day's Range | 0.2200 - 0.2600 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2.81k |
- Reuters
Moderna expects to price its COVID vaccine at about $130 in the US
Moderna Inc expects to price its COVID-19 vaccine at around $130 per dose in the U.S. going forward as purchases move to the private sector from the government, the company’s president Stephen Hoge said in an interview on Monday. “There are different customers negotiating different prices right now, which is why it's a little bit complicated,” Hoge said ahead of a Congressional hearing run by Democratic U.S. Senator Bernie Sanders on Moderna’s pricing plans. Moderna previously said it was considering pricing its COVID vaccine in a range of $110 to $130 per dose in the United States, similar to the range Pfizer Inc said in October it was considering for its rival COVID shots sold in partnership with BioNTech.
- Motley Fool
2 Undervalued Stocks to Buy Today to Prepare for the Next Bull Market
Rewards that the next bull market will bring are being built right now by farsighted investors who can find opportunities among today's discounted stocks. While there's no telling exactly when a bull market will develop, planting the seeds of success by buying some shares of cheap yet high-quality companies out there right now is a good move. With that in mind, here are two businesses you're probably acquainted with that are priced for a no-brainer purchase -- and have a good shot at flourishing in the next bull market and beyond.
- Motley Fool
1 Top Healthcare Stock That Could Make You Richer in the Next Decade
On that note, Pfizer (NYSE: PFE) has a habit of making its investors wealthier via its dividends and share repurchasing activity, and there's no reason to suspect that'll change through at least 2030. If you invested $5,000 in Pfizer a decade ago, right now you'd be happy to see that its total return in that period was around $10,900. In the next 10 years, there's no guarantee that it'll repeat that exact performance, but there are reasons to believe that it'll still be a good stock to own for the purposes of collecting its dividend and perhaps also experiencing share price appreciation over the long run.
